title: [Sarcomas of the vulva. Report of 2 cases].
abstract: We report two cases of vulvar sarcomas that are our Institutional experience in 29 years. The first case was a teenager of 14 years-old with a low grade leiomyosarcoma surgically treated. Along a 22 years follow-up the disease has had four local recurrences of more than 5 cm each one: two after surgery and two after surgery plus chemotherapy and surgery plus radiotherapy respectively. She is alive disease evidence after two years from the last combined treatment. The second one, was a 26 years-old patient with a malignant schwannoma of 12 cm in diameter treated with combined radical surgery, radiotherapy, and chemotherapy. She is alive and without disease evidence 52 months after surgery. We emphasized that these tumors are very rare and the fact that the first patient is the youngest and with more years of follow up according the bibliography consulted. Treatment of vulvar sarcomas is radical local excision followed mainly by radiotherapy with infiltrating margins. The value of postoperative adjuvant chemotherapy is uncertain. According to the natural history and behavior of vulvar sarcomas, we conclude that the elective treatment of these tumors should be carry out in institutions of high level.
authors.affiliation: Servicio de Oncología, Hospital General de México, SSa.
authors.forename: A
authors.initials: A
authors.lastname: Torres Lobatón
authors.forename: H
authors.initials: H
authors.lastname: Cruz Ortiz
authors.forename: G
authors.initials: G
authors.lastname: Rojo Herrera
authors.forename: L
authors.initials: L
authors.lastname: Avila Medrano
mesh_terms: D000008:Abdominal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D000293:Adolescent; D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001472:Bartholin's Glands; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D015653:Cystectomy; D003560:Cysts / Q000175:diagnosis; D003606:Dacarbazine / Q000008:administration & dosage / Q000627:therapeutic use; D003937:Diagnosis, Differential; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007890:Leiomyosarcoma / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery; D009364:Neoplasm Recurrence, Local; D009442:Neurilemmoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D010386:Pelvic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D011867:Radioisotope Teletherapy; D012189:Retrospective Studies; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000556:secondary / Q000601:surgery; D014846:Vulvar Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide